行情

GILD

GILD

吉利德科技
NASDAQ

实时行情|Nasdaq Last Sale

62.98
-0.22
-0.35%
盘后: 62.98 0 0.00% 19:51 01/17 EST
开盘
63.50
昨收
63.20
最高
63.50
最低
62.57
成交量
1,345.76万
成交额
--
52周最高
70.50
52周最低
60.89
市值
796.79亿
市盈率(TTM)
29.92
分时
5日
1月
3月
1年
5年

分析师评级

28位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

EPS

GILD 新闻

  • Why This Biotech's Next Chapter Is 'TBD' Amid Deal-Making Dearth
  • Investor's Business Daily.1天前
  • GILD or EXEL: Which Is the Better Value Stock Right Now?
  • Zacks.1天前
  • Gilead Sciences Option Alert: Fri $63 Calls Sweep (52) above Ask!: 1040 @ $0.3 vs 232 OI; Earnings 2/3 After Close [est] Ref=$63.09
  • Benzinga.1天前
  • Novo Nordisk's Ozempic Gets FDA Nod for CV Risk Reduction
  • Zacks.1天前

更多

所属板块

生物技术和医学研究
-0.16%
制药与医学研究
+0.06%

热门股票

名称
价格
涨跌幅

GILD 简况

Gilead Sciences, Inc. is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company's portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions. Its products for HIV/AIDS patients include Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Truvada, Emtriva, Tybost and Vitekta. Its products for patients with liver diseases include Vemlidy, Epclusa, Harvoni, Sovaldi, Viread and Hepsera. It offers Zydelig to patients with hematology/oncology diseases. Its products for patients with various cardiovascular diseases include Letairis, Ranexa and Lexiscan. Its products for various inflammation/respiratory diseases include Cayston and Tamiflu. It had operations in more than 30 countries, as of December 31, 2016.
展开

Webull提供Gilead Sciences, Inc.的股票价格,实时市场报价,专业分析师评级,深度图表和免费的股票新闻,以帮助您做出投资决策。